Filtros : "Sanofi" Removido: "Nicolau, José Carlos" Limpar

Filtros



Refine with date range


  • Source: Jacc-heart failure. Unidade: FM

    Subjects: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 09 out. 2024.
    • APA

      Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
    • NLM

      Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
    • Vancouver

      Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
  • Source: Acta dermato-venereologica. Unidade: FM

    Subjects: DERMATITE, CRIANÇAS, SINAIS E SINTOMAS

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      WOLLENBERG, Andreas et al. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta dermato-venereologica, v. 102, 2022Tradução . . Disponível em: https://doi.org/10.2340/actadv.v102.854. Acesso em: 09 out. 2024.
    • APA

      Wollenberg, A., Marcoux, D., I, J. S., Aoki, V., Baselga, E., Zhang, H., et al. (2022). Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta dermato-venereologica, 102. doi:10.2340/actadv.v102.854
    • NLM

      Wollenberg A, Marcoux D, I JS, Aoki V, Baselga E, Zhang H, Levit NA, Taieb A, Rossi AB. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis [Internet]. Acta dermato-venereologica. 2022 ; 102[citado 2024 out. 09 ] Available from: https://doi.org/10.2340/actadv.v102.854
    • Vancouver

      Wollenberg A, Marcoux D, I JS, Aoki V, Baselga E, Zhang H, Levit NA, Taieb A, Rossi AB. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis [Internet]. Acta dermato-venereologica. 2022 ; 102[citado 2024 out. 09 ] Available from: https://doi.org/10.2340/actadv.v102.854
  • Source: Journal of investigational allergology and clinical immunology. Unidades: FMRP, FM

    Subjects: DERMATITE DE CONTATO, PREVALÊNCIA, QUALIDADE DE VIDA

    PrivadoAcesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      ARRUDA, Luisa Karla de Paula et al. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study. Journal of investigational allergology and clinical immunology, v. 31, n. 3, p. 236-245, 2021Tradução . . Disponível em: https://doi.org/10.18176/jiaci.0478. Acesso em: 09 out. 2024.
    • APA

      Arruda, L. K. de P., Yang, A. C., Aoki, V., Criado, R. F. J., Pires, M. C., Lupi, O., et al. (2021). Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study. Journal of investigational allergology and clinical immunology, 31( 3), 236-245. doi:10.18176/jiaci.0478
    • NLM

      Arruda LK de P, Yang AC, Aoki V, Criado RFJ, Pires MC, Lupi O, Fabricio LHZ, Richman D, Silvi S. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study [Internet]. Journal of investigational allergology and clinical immunology. 2021 ; 31( 3): 236-245.[citado 2024 out. 09 ] Available from: https://doi.org/10.18176/jiaci.0478
    • Vancouver

      Arruda LK de P, Yang AC, Aoki V, Criado RFJ, Pires MC, Lupi O, Fabricio LHZ, Richman D, Silvi S. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study [Internet]. Journal of investigational allergology and clinical immunology. 2021 ; 31( 3): 236-245.[citado 2024 out. 09 ] Available from: https://doi.org/10.18176/jiaci.0478
  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 09 out. 2024.
    • APA

      Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
    • NLM

      Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
    • Vancouver

      Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: REVASCULARIZAÇÃO MIOCÁRDICA, SOBREVIDA, DIABETES MELLITUS, CORONARIOPATIA

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      FARKOUH, Michael E et al. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, v. 73, n. 6, p. 629-638, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.11.001. Acesso em: 09 out. 2024.
    • APA

      Farkouh, M. E., Domanski, M., Dangas, G. D., Godoy, L. C., Mack, M. J., Siami, F. S., et al. (2019). Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, 73( 6), 629-638. doi:10.1016/j.jacc.2018.11.001
    • NLM

      Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
    • Vancouver

      Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
  • Source: Cardiovascular drugs and therapy. Unidade: FM

    Subjects: HIPERCOLESTEROLEMIA, ERROS INATOS DO METABOLISMO, ENZIMAS PROTEOLÍTICAS, FATORES DE RISCO

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      GINSBERG, Henry N et al. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, v. 33, n. 1, p. 69-76, 2019Tradução . . Disponível em: https://doi.org/10.1007/s10557-019-06852-6. Acesso em: 09 out. 2024.
    • APA

      Ginsberg, H. N., Tuomilehto, J., Hovingh, G. K., Cariou, B., Santos Filho, R. D. dos, Brown, A. S., et al. (2019). Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, 33( 1), 69-76. doi:10.1007/s10557-019-06852-6
    • NLM

      Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2024 out. 09 ] Available from: https://doi.org/10.1007/s10557-019-06852-6
    • Vancouver

      Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2024 out. 09 ] Available from: https://doi.org/10.1007/s10557-019-06852-6
  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 09 out. 2024.
    • APA

      Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
    • NLM

      Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
    • Vancouver

      Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
  • Source: Circulation-cardiovascular interventions. Unidade: FM

    Subjects: INFARTO DO MIOCÁRDIO, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA, TROMBOSE

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      DILLINGER, Jean-Guillaume e NICOLAU, Jose C. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, v. 11, n. 6, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084. Acesso em: 09 out. 2024.
    • APA

      Dillinger, J. -G., & Nicolau, J. C. (2018). Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, 11( 6). doi:10.1161/CIRCINTERVENTIONS.118.006084
    • NLM

      Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 out. 09 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
    • Vancouver

      Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 out. 09 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
  • Source: Archives of endocrinology metabolism. Unidade: FM

    Subjects: PACIENTES INTERNADOS, CUSTOS DOS CUIDADOS DE SAÚDE, DOENÇAS CARDIOVASCULARES, HIPERCOLESTEROLEMIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BAHIA, Luciana R. et al. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, v. 62, n. 3, p. 303-308, 2018Tradução . . Disponível em: https://doi.org/10.20945/2359-3997000000030. Acesso em: 09 out. 2024.
    • APA

      Bahia, L. R., Santos, R. D., Araujo, D. V., Rosa, R. S., & Bahia, L. R. (2018). Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, 62( 3), 303-308. doi:10.20945/2359-3997000000030
    • NLM

      Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 out. 09 ] Available from: https://doi.org/10.20945/2359-3997000000030
    • Vancouver

      Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 out. 09 ] Available from: https://doi.org/10.20945/2359-3997000000030
  • Source: Intensive care medicine. Unidade: FM

    Subjects: CHOQUE CARDIOGÊNICO, ESTUDOS RANDOMIZADOS, CUIDADOS CRÍTICOS, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MEBAZAA, Alexandre e HAJJAR, Ludhmila Abrahao. Management of cardiogenic shock complicating myocardial infarction. Intensive care medicine, v. 44, n. 6, p. 760-773, 2018Tradução . . Disponível em: https://doi.org/10.1007/s00134-018-5214-9. Acesso em: 09 out. 2024.
    • APA

      Mebazaa, A., & Hajjar, L. A. (2018). Management of cardiogenic shock complicating myocardial infarction. Intensive care medicine, 44( 6), 760-773. doi:10.1007/s00134-018-5214-9
    • NLM

      Mebazaa A, Hajjar LA. Management of cardiogenic shock complicating myocardial infarction [Internet]. Intensive care medicine. 2018 ; 44( 6): 760-773.[citado 2024 out. 09 ] Available from: https://doi.org/10.1007/s00134-018-5214-9
    • Vancouver

      Mebazaa A, Hajjar LA. Management of cardiogenic shock complicating myocardial infarction [Internet]. Intensive care medicine. 2018 ; 44( 6): 760-773.[citado 2024 out. 09 ] Available from: https://doi.org/10.1007/s00134-018-5214-9
  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 09 out. 2024.
    • APA

      Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
    • NLM

      Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
    • Vancouver

      Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
  • Source: Circulation. Unidade: FM

    Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 09 out. 2024.
    • APA

      Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
    • NLM

      Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 out. 09 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
    • Vancouver

      Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 out. 09 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
  • Source: European journal of preventive cardiology. Unidade: FM

    Subjects: ESTATINAS, DOENÇAS CARDIOVASCULARES, COLESTEROL, LIPOPROTEÍNAS LDL

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      DANCHIN, Nicolas e SANTOS, Raul D. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, v. 25, n. 10, p. 1087-1094, 2018Tradução . . Disponível em: https://doi.org/10.1177/2047487318777079. Acesso em: 09 out. 2024.
    • APA

      Danchin, N., & Santos, R. D. (2018). Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, 25( 10), 1087-1094. doi:10.1177/2047487318777079
    • NLM

      Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 out. 09 ] Available from: https://doi.org/10.1177/2047487318777079
    • Vancouver

      Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 out. 09 ] Available from: https://doi.org/10.1177/2047487318777079
  • Source: Nature reviews disease primers. Unidade: FM

    Subjects: HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS CARDIOVASCULARES

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      DEFESCHE, Joep C. et al. Familial hypercholesterolaemia. Nature reviews disease primers, v. 3, 2017Tradução . . Disponível em: https://doi.org/10.1038/nrdp.2017.93. Acesso em: 09 out. 2024.
    • APA

      Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Santos Filho, R. D. dos, & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews disease primers, 3. doi:10.1038/nrdp.2017.93
    • NLM

      Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 out. 09 ] Available from: https://doi.org/10.1038/nrdp.2017.93
    • Vancouver

      Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 out. 09 ] Available from: https://doi.org/10.1038/nrdp.2017.93
  • Source: American journal of kidney diseases. Unidade: FM

    Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 09 out. 2024.
    • APA

      Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
    • NLM

      Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 out. 09 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
    • Vancouver

      Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 out. 09 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
  • Source: Lancet respiratory medicine. Unidade: FM

    Subjects: QUALIDADE DE VIDA, CUIDADOS PALIATIVOS, DOENÇAS PULMONARES INTERSTICIAIS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      KREUTER, Michael e KAIRALLA, Ronaldo Adib. Palliative care in interstitial lung disease: living well. Lancet respiratory medicine, v. 5, n. 12, p. 968-980, 2017Tradução . . Disponível em: https://doi.org/10.1016/S2213-2600(17)30383-1. Acesso em: 09 out. 2024.
    • APA

      Kreuter, M., & Kairalla, R. A. (2017). Palliative care in interstitial lung disease: living well. Lancet respiratory medicine, 5( 12), 968-980. doi:10.1016/S2213-2600(17)30383-1
    • NLM

      Kreuter M, Kairalla RA. Palliative care in interstitial lung disease: living well [Internet]. Lancet respiratory medicine. 2017 ; 5( 12): 968-980.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/S2213-2600(17)30383-1
    • Vancouver

      Kreuter M, Kairalla RA. Palliative care in interstitial lung disease: living well [Internet]. Lancet respiratory medicine. 2017 ; 5( 12): 968-980.[citado 2024 out. 09 ] Available from: https://doi.org/10.1016/S2213-2600(17)30383-1

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024